title: Peroxynitrite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice.
abstract: BACKGROUND
  (MRL)-lpr/lpr mice spontaneously develop autoimmune disease characterized by arthritis and glomerulonephritis. Nitric oxide is postulated to play a role in the disease pathogenesis, as mice treated with the nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine (NMMA) show markedly reduced manifestations of the disease. The purpose of this study was to examine the role of peroxynitrite in disease development in MRL-lpr/lpr mice.
  
  
  METHODS
  We examined kidney extracts from control and MRL-lpr/lpr mice for nitrotyrosine by immunoblot with a rabbit polyclonal anti-nitrotyrosine antibody. Catalase activity was determined spectrophotometrically or by activity staining of native polyacrylamide gels. In some experiments, we studied the ability of peroxynitrite and other agents to modify purified catalase in vitro.
  
  
  RESULTS
  Kidney extracts from diseased mice had elevated levels of nitrotyrosine, and decreased levels of catalase activity and protein, relative to control mice. MRL-lpr/lpr mice treated with NMMA in vivo had decreased levels of nitrotyrosine, and demonstrated a partial restoration of both catalase activity and protein levels. Treatment of catalase in vitro with peroxynitrite or tetranitromethane at pH 8.0 resulted in protein nitration and a decrease in catalase activity. 1,3-morpholinosydnonimine (SIN-1), a peroxynitrite generator, also decreased the activity of catalase.
  
  
  CONCLUSIONS
  These observations suggest that peroxynitrite formation, with an associated decrease in catalase activity and general decrease in antioxidant enzyme activity, may result in increased levels of hydrogen peroxide and other oxidants that can contribute to the pathogenesis of disease in MRL-lpr/lpr mice.
authors.affiliation: Apex Bioscience, Inc., Durham, North Carolina, USA.
authors.forename: T
authors.initials: T
authors.lastname: Keng
authors.forename: C T
authors.initials: CT
authors.lastname: Privalle
authors.forename: G S
authors.initials: GS
authors.lastname: Gilkeson
authors.forename: J B
authors.initials: JB
authors.lastname: Weinberg
mesh_terms: D000818:Animals; D001168:Arthritis / Q000201:enzymology* / Q000517:prevention & control; D001327:Autoimmune Diseases / Q000201:enzymology* / Q000517:prevention & control; D002374:Catalase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002417:Cattle; D004249:DNA Damage; D005921:Glomerulonephritis / Q000201:enzymology* / Q000517:prevention & control; D015151:Immunoblotting; D007668:Kidney / Q000201:enzymology / Q000473:pathology; D008099:Liver / Q000201:enzymology / Q000473:pathology; D051379:Mice; D019463:Mice, Inbred MRL lpr; D018345:Mice, Knockout; D008981:Molsidomine / Q000031:analogs & derivatives / Q000494:pharmacology; D009566:Nitrates / Q000037:antagonists & inhibitors / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D018384:Oxidative Stress; D017382:Reactive Oxygen Species; D013482:Superoxide Dismutase / Q000378:metabolism; D019323:omega-N-Methylarginine / Q000627:therapeutic use
chemical_list: D009566:Nitrates; D020030:Nitric Oxide Donors; D017382:Reactive Oxygen Species; C039642:peroxynitric acid; D019323:omega-N-Methylarginine; C002385:linsidomine; D008981:Molsidomine; D002374:Catalase; D013482:Superoxide Dismutase